Volume 27, Number 5—May 2021
Research

## Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil

Natalia Fintelman-Rodrigues, Aline P.D. da Silva, Monique Cristina dos Santos, Felipe B. Saraiva, Marcelo A. Ferreira, João Gesto, Danielle A.S. Rodrigues, André M. Vale, Isaclaudia G. de Azevedo, Vinícius C. Soares, Hui Jiang, Hongdong Tan, Diogo A. Tschoeke, Carolina Q. Sacramento, Fernando A. Bozza, Carlos M. Morel, Patrícia T. Bozza, and Thiago Moreno L. Souzaø Author affiliations: Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil (N. Fintelman-Rodrigues, A.P.D. da Silva, M.C. dos Santos, F.B. Saraiva, M.A. Ferreira, J. Gesto, I.G. de Azevedo, V.C. Soares, C.Q. Sacramento, F.A. Bozza, C.M. Morel, P.T. Bozza, T.M.L. Souza); Universidade Federal do Rio de Janeiro, Rio de Janeiro (D.A.S. Rodrigues, A.M. Vale, V.C. Soares, D.A. Tschoeke); MGI Tech Co., Ltd., Shenzhen, China (H. Jiang, H. Tan); D’Or Institute for Research and Education (F.A. Bozza) Main Article

Table
Characteristics of patients reinfected with severe acute respiratory syndrome coronavirus 2, Brazil, 2020*

| Characteristic | Patient A | Patient B | Patient C | Patient D |
| :---: | :---: | :---: | :---: | :---: |
| Primo-infection |  |  |  |  |
| Sex | M | F | M | F |
| Age, y | 54 | 57 | 34 | 34 |
| Concurrent conditions | None | Discoid lupus erythematosus | None | None |
| Date of symptom onset | March 21 | March 26 | Asymptomatic | March 31 |
| Symptoms | Headache | Mild diarrhea | No | Mild diarrhea |
| N1 RT-PCR, $\log _{10}$ copies/mL | 5.12 | 3.21 | 3.83 | 3.01 |
| Date conducted | March 23 | March 24 | March 24 | April 2 |
| RNP RT-PCR (internal control), $C_{t}$ | 26.5 | 26.66 | 27.41 | 28.48 |
| Serology ${ }^{+}$ | $\lg \mathrm{M}, \lg A, \lg G$ detected | $\lg \mathrm{M}, \lg$, $\operatorname{IgG}$ detected | $\lg \mathrm{M}, \lg$, $\operatorname{IgG}$ detected | IgM, IgA, IgG detected |
| $\mathrm{PRNT}_{90} / 25 \mathrm{uL}+$ | $<1: 4$ | <1:4 | <1:4 | <1:4 |
| Sequencing | Not enough sample | Emerging clade 19A | emerging clade 20B | Not enough sample |
| ID | N/A | EPI_ISL_636834 | EPI_ISL_636836 | NA |


| Second infection |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Date of onset illness | May 25 | May 26 | May 27 | May 30 |
| Symptoms | Fever, dry cough, tiredness, body ache, anosmia, ageusia | Fever, diarrhea, headache, body ache, anosmia, ageusia | Fever, nausea, tiredness, headache, body ache | Dry cough, diarrhea, tiredness, headache, body ache, anosmia, ageusia |
| RT-PCR, $\log _{10}$ | 7.31 | 7.42 | 5.18 | 9.61 |


| Characteristic | Patient A | Patient B | Patient C | Patient D |
| :---: | :---: | :---: | :---: | :---: |
| Date conducted | May 29 | May 29 | May 29 | May 29 |
| RNP RT-PCR <br> internal control | 24.6 | 27.06 | 28.12 | 24.5 |
| Serology results $\ddagger$ | $\lg \mathrm{M}, \lg \mathrm{A}, \lg \mathrm{g}$ detected | $\lg \mathrm{M}, \lg \mathrm{A}, \lg \mathrm{g}$ detected | $\lg \mathrm{M}^{\prime}, \lg A, \lg \mathrm{~g}$ undetectable | $\lg$, $\lg A, \lg \mathrm{G}$ undetectable |
| PRNT ${ }_{90} / 25$ uL $\ddagger$ | 1:16 | <1:4 | <1:4 | <1:4 |
| Sequencing | Emerging clade 20B | Emerging clade 20B | Emerging clade 20B | Emerging clade 20B |
| Accession ID | EPI_ISL_636737 | EPI_ISL_636835 | EPI_ISL_636837 | EPI_ISL_636838 |


*N1, nucleocapside gene; NA, not available; $\mathrm{PRNT}_{90}, 90 \%$ plaque-reduction neutralization test; RNP, human RNase P gene; RTPCR, reverse transcription PCR. †Tests conducted March 27.£Tests conducted June 3. §Tests conducted July 9. 9 Tests conducted August 10.
Main Article

Page created: April 01, 2021
Page updated: April 01, 2021
Page reviewed: April 01, 2021

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

